Group 1 - The core point of the news is that Tailin Bio has recently obtained three invention patents through its wholly-owned subsidiaries, indicating a focus on innovation and development in the biotechnology sector [1] - The patents include a "microbial elution solution and its preparation method and application" and a "sterile connector and sterile connection method," showcasing the company's advancements in medical technology [1] - For the fiscal year 2024, Tailin Bio's revenue composition is projected to be 90.04% from the pharmaceutical industry and 9.96% from other businesses, highlighting the company's strong reliance on its core pharmaceutical operations [1] Group 2 - As of the latest report, Tailin Bio has a market capitalization of 3.6 billion yuan, reflecting its position in the market [2]